Tesamorelin (brand name Egrifta) is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification improves bioavailability and resistance to enzymatic degradation.
Unlike exogenous growth hormone (HGH), tesamorelin stimulates the body’s own pituitary gland to produce and release growth hormone in a pulsatile, physiological pattern. This preserves the natural feedback mechanisms that prevent excessive GH levels and associated side effects.
Originally developed and approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, tesamorelin has gained significant popularity in the anti-aging and body composition optimization community for its ability to increase GH levels, reduce visceral fat, and improve body composition without the risks of direct GH administration.
Looking for the best vendor deals?
Compare prices across 10+ peptide and anabolic vendors. Find the best quality at the lowest price.
Compare Vendors